Connect with us

Private Companies

MagicMed’s Natalie Dolphin: PsyAI™ Designed to Streamline Pharmaceutical Design

Psychedelic Finance recently interviewed MagicMed Executive Natalie Dolphin about the company’s proprietary PsyAI™ and the Psybrary™

Published

2 years ago

on

This article was originally published by https://investingnews.com/company-news/magicmed-natalie-dolphin-psyai-designed-to-streamline-pharmaceutical-design/
Psychedelic Finance recently interviewed MagicMed Executive Natalie Dolphin about the company’s proprietary PsyAI™ and the Psybrary™. In the interview, Dolphin likens PsyAI™ to a key and mental health indications a lock, whereby MagicMed, “creates a large library of potential keys.” MagicMed’s Psybrary™ is designed to become one of the leading providers of novel drug candidates for the biotechnology and pharmaceutical industries. Read the full interview here.  
Request an Investor Kit:

MagicMed Industries

Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredited-investor-definition/ or search for "accredited investor" in the search bar above.
 

By completing this form, you are giving consent to receive communication from MagicMed Industries using the contact information you provide. And remember you can unsubscribe at any time.

 
psychedelics outlook
 

New Report: Psychedelics Outlookfor Investors

 
What’s ahead for this new market?Find out in our exclusive psychedelics outlook INNvestor Report.
The post MagicMed’s Natalie Dolphin: PsyAI™ Designed to Streamline Pharmaceutical Design appeared first on Investing News Network.

Read More

Related Topics:
Continue Reading

Trending